{'fraction_non_alphanumeric': 0.02843216896831844, 'fraction_numerical': 0.012997562956945572, 'mean_word_length': 4.951690821256038, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Long-term use of three-monthly injectable contraceptive DMPA not linked to breast cancer.


 Depot medroxyprogesterone acetate (DMPA) is a three-month, highly effective, injectable hormonal method of contraception. The method is also known as Depo-Provera. The UNDP/UNFPA/WHO/World Bank Special Program of Research, Development, and Research Training in Human Reproduction, in collaboration with the University of Otago Medical School, Dunedin, New Zealand, and the Fred Hutchinson Cancer Research Center in Seattle, Washington, conducted a secondary analysis of combined data on breast cancer and DMPA which had been collected in two studies previously conducted by the three organizations in Kenya, Mexico, New Zealand, and Thailand. 1768 women with breast cancer, mostly younger than age 55 years, and 13,905 women who did not have the disease participated in the study. The study determined that women who use DMPA are not at increased overall risk of breast cancer compared to women who have never used it. The study also concludes that the use of DMPA should not be restricted on the grounds of breast cancer risk. Study findings were published in the March 8, 1995, issue of the Journal of the American Medical Association.
